Key facts
- This page summarizes Laura Shawver's Form 4 filing for ARS Pharmaceuticals, Inc. (SPRY).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 26 Jun 2026, 16:15.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.